CD123-CD16-NK Cells Immunotherapy for AML

Exclusion Criteria

• •1. Specific AML Subtype:
• •Diagnosed with Acute Promyelocytic Leukemia(APL).
• •2. CD123 Expression:
• •Flow cytometry shows CD123 negative or CD123 expression level less than 20%.
• •3. Prior Treatment Toxicity:
• •Persistent non-hematologic toxicity of grade 2 or higher related to previous treatments.
• •4. GVHD Requiring Immunosuppression:
• •Patients requiring immunosuppressants for grade II-IV acute Graft-Versus-Host Disease (GVHD).
• •5. Recent Steroid Treatment:
• •Systemic steroid treatment within 7 days prior to first study drug treatment (excluding topical and inhaled corticosteroids or short-term prophylactic steroid treatment).
• •6. Severe Cardiovascular and Cerebrovascular Diseases:
• •Certain cardiovascular and cerebrovascular diseases within 6 months prior to first dose.
• •New York Heart Association (NYHA) classification ≥3 or uncontrolled malignant arrhythmias.Other cardiovascular and cerebrovascular diseases deemed unsuitable by the investigator.
• •7. Pregnancy and Lactation:
• •Pregnant or breastfeeding women (the safety of this treatment for unborn babies is unknown).
• •For female participants, pregnancy must be confirmed negative by serum or urine pregnancy test within 48 hours before infusion.
• •8. Infections:
• •Active Hepatitis B,Hepatitis C virus infection, Peripheral blood CMV-DNA ≥500 copies/mL, HIV/AIDS infection and any uncontrolled active infection.
• •9. Allergic Reactions:
• •Allergic to immunotherapy and related drugs.
• •10. Neurological Diseases:
• •Neurological diseases such as neurodegenerative diseases, primary central nervous system tumors/infections, multiple sclerosis, epilepsy, severe peripheral neuropathy, etc.